EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study

Debora Santonocito iD, Giuliana Greco, Maria Grazia Sarpietro iD, Aurélie Schoubben iD, Claudia Sciacca iD, Giuseppe Romeo iD, Katia Mangano, Carmelo Puglia iD

International Journal of Molecular Sciences · 07.12.2025 · 26 (24) · 11827

DOI: 10.3390/ijms262411827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.12.2025. Verfasst von Debora Santonocito und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug and Health Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy. Hauptthemen laut MEDLINE: Nanoparticles, Multiple Sclerosis, Drug Carriers, Lipids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project Piaceri "Valutazione degli Effetti del Trattamento con Diroximel Fumarato in Nanoparti-celle Lipidiche Solide (DRF-SLN) per via Intranasale in Modelli…, University of Catania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diroximel fumarate (DRF) is an orally administered prodrug used in multiple sclerosis (MS) treatment. Although it exhibits better gastrointestinal (GI) tolerability than its analogues, many patients still discontinue therapy due to frequent GI adverse events. To overcome these limitations, alternative drug delivery systems that bypass the GI tract are needed. Direct nose-to-brain delivery represents a promising approach to circumvent the blood–brain barrier and target the central nervous system; however, limited nasal mucosal absorption and the small volume of the nasal cavity pose significant challenges. Solid lipid nanoparticles (SLNs) can potentially overcome these obstacles by enhancing drug bioavailability and protecting against enzymatic degradation. This research aimed to develop an innovative intranasal nanoformulation of DRF to improve brain targeting and patient compliance. DRF-loaded SLNs were prepared using a solvent-diffusion technique with stearic acid as the lipid phase and Poloxamer 188 as the surfactant. The obtained nanoparticles displayed favorable technological characteristics, with a mean diameter of 210 nm, a polydispersity index of 0.17, and a zeta potential of −36 mV, suggesting good long-term stability. Interactions between SLNs and biomembrane models (MLV) were also studied to elucidate their cellular uptake mechanism. Future work will focus on evaluating the in vivo efficacy of this novel nanoformulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesMultiple SclerosisDrug CarriersLipidsFumaratesHumansParticle SizeAdministration, IntranasalAnimalsDrug Delivery SystemsLiposomes

Stichwörter der Autor:innen

diroximel fumaratelipid nanoparticlesmultiple sclerosisnose-to-brain administration

Substanzen

Drug CarriersLipidsLipid NanoparticlesFumaratesdiroximel fumarateLiposomes

Autor:innen und Institutionen

  • Department of Drug and Health Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.
  • NANOMED-Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.
  • Department of Pharmaceutical Sciences, University of Perugia, Via del Giochetto 5, 06122 Perugia, Italy.
  • Department of Chemical Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.
  • Department of Biomedical and Biotechnological Sciences, University of Catania, Via Santa Sofia 97, 95123 Catania, Italy.

ORCID-Profile: Debora Santonocito, Maria Grazia Sarpietro, Aurélie Schoubben, Claudia Sciacca, Giuseppe Romeo, Carmelo Puglia

Förderung

  • Project Piaceri "Valutazione degli Effetti del Trattamento con Diroximel Fumarato in Nanoparti-celle Lipidiche Solide (DRF-SLN) per via Intranasale in Modelli…
  • University of Catania

Zitieren

APA

Santonocito, D., Greco, G., Sarpietro, M. G., Schoubben, A., Sciacca, C., Romeo, G., Mangano, K., & Puglia, C. (2025). Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study. International Journal of Molecular Sciences, 26(24), 11827. https://doi.org/10.3390/ijms262411827

Vancouver

Santonocito D, Greco G, Sarpietro MG, Schoubben A, Sciacca C, Romeo G, et al. Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study. International Journal of Molecular Sciences. 2025;26(24):11827. doi:10.3390/ijms262411827

BibTeX
@article{Santonocito2025,
  author = {Santonocito, Debora and Greco, Giuliana and Sarpietro, Maria Grazia and Schoubben, Aurélie and Sciacca, Claudia and Romeo, Giuseppe and Mangano, Katia and Puglia, Carmelo},
  title = {Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {24},
  pages = {11827},
  doi = {10.3390/ijms262411827}
}
Kostenlos starten →